TrialBreast cancer research and treatment2013

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

S Ohno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.